CTRI/2021/12/038411已完成未知
A Randomized, Multicenter, Single-dose, Two-treatment, Single-period, Parallel, Bioequivalence Study of Mylan’s Paliperidone Prolonged release Suspension for Injection, 175 mg and Janssen-Cilag’s Trevicta® prolonged release suspension for injection, 175 mg in Subjects with Schizophrenia
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 242
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •Subject candidates must fulfill all of the following inclusion criteria to be eligible for participation in the study, unless otherwise specified:
- •1.Male or on-pregnant, non-lactating female subjects between 18 and 65 years of age (both inclusive)
- •2.Patients having a clinical diagnosis of schizophrenia as per DSM V criteria.
- •3.Patients without established tolerability and responsiveness to oral paliperidone/risperidone or injectable paliperidone, will be tested for tolerability of Paliperidone during screening
- •4.Subjects who are clinically stable with no hospitalizations for exacerbation of psychiatric symptoms
- •5.Weight:Each subject is required to weigh at least 50 kg (110 lbs) for men and 48 kg (106 lbs) for women and have a Body Mass Index (BMI) value less than or equal to 35.0 kg/m2 but greater than or equal to 18.0 kg/m2.
排除标准
- •1.Institutionalized subjects.
- •2.Subjects with history of alcohol or drug-dependence as per DSM-V criteria
- •3.Subjects with ingestion of any alcoholic beverage within the 24 hours
- •4.Subjects with ingestion of risperidone long acting injection
- •5.Subjects with depot injection or implant of any drug other than hormonal contraceptive or hormone replacement therapy
- •6.Subjects currently being treated with Clozapine, monoamine oxidase inhibitor (MAOI) antidepressants, electroconvulsive therapy
- •7.Use of any medication, herbal supplement, or vitamin known to induce or inhibit hepatic enzyme activity
- •8.Subjects with dementia related psychosis
- •9.Subjects with Clinical Global Impression - Severity of illness (CGI-S) score of 5 or more
- •10.Subjects with suicidal ideation
- •11.Subjects with a history of Neuroleptic Malignant Syndrome (NMS)
- •12.History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychological, genitourinary, musculoskeletal disease, uncontrolled metabolic diseases, clinically significant laboratory results or malignancies by the Principal Investigator or Medical Sub-Investigator.
- •13.Use of drugs that prolong the QTc interval,
- •14.Subjects with positive HIV, hepatitis B antigen, hepatitis C antibody, RPR or VDRL test
- •15.Subjects with positive urine drug screen
- •16.Subjects with history or presence of tardive dyskinesia, seizures idiopathic Parkinson’s disease, cognitive and motor impairment.
- •17.Subjects with donation or loss of blood or plasma
- •18.Subjects with participation in any interventional clinical study
- •19.Subjects with allergy or hypersensitivity to paliperidone, risperidone, other related products, or any inactive ingredients
- •20.Subjects has clinical signs and symptoms consistent with COVID-19 or had severe COVID-19
研究者
相似试验
尚未招募
不适用
To assess blood concentration of Paliperidone Prolonged Release Injectable Suspension at different times in patients with Schizophrenia following single doseCTRI/2021/12/038783Mylan Laboratories Limited
已完成
不适用
A study to compare two forms/formulations of Paclitaxel Injectable Suspension in metastatic Breast cancer patientsCTRI/2020/09/028155Mylan Laboratories Limited111
招募中
不适用
To assess blood concentration of Paliperidone Prolonged Release Injectable Suspension at different times in patients with Schizophrenia following multiple dosesCTRI/2021/12/038455Mylan Laboratories Limited216
已完成
不适用
Pharmacokinetic study of paliperidone palmitate in patients with schizophrenia.CTRI/2018/08/015469Mylan Laboratories Limited264
尚未招募
不适用
To assess blood concentration of Paliperidone Prolonged Release Injectable Suspension at different times in patients with Schizophrenia following multiple dosesCTRI/2021/11/038048Mylan Laboratories Limited